This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Regenerative Medicine Markets


Figure 2.1: Geographic Distribution of Tissue Engineering Firms in Major Markets 32Figure 2.2: The Potential Uses of Embryonic Stem Cells 33Figure 2.3: Progress of Cell Therapy Product Research, 2012 34Figure 2.4: Commercially Available Cell Therapy Products, 2012 35Figure 2.5: Disease Focus by Regenerative Medicine 39Figure 2.6: Estimated Completion Dates for Stem Cell Based Clinical Trials Targeting Type 1 Diabetes, 2009-2015 45Figure 2.7: Number of Clinical Trials by Targeted Condition, 2005-2011 45Figure 2.8: Concentration of European Cell Therapy Firms, 2012 46Figure 2.9: European Stem Cell Platforms by Cell Source 47Figure 2.10: Autologous vs. Allogeneic Stem Cell Therapy Firms in Europe, 2012 48Figure 2.11: Autologous and Allogeneic Somatic Cell Therapy Firms in Europe, 2012 48Figure 2.12: Sponsors of Cell Therapy Clinical Trials in the U.K., 2012 52Figure 2.13: Clinical Trials Involving Allogeneic vs. Autologous Cell Therapy Products in the U.K., 2012 52Figure 2.14: Cell Types Involved in the U.K. Cell Therapy Clinical Trials, 2012 53Figure 2.15: U.K. Cell Therapy Clinical Trials by Indication, 2012 54Figure 2.16: Cell Culture Products Market by Segment, 2012 55Figure 2.17: Market for Reagents Used in Cell Culture, 2012-2019 56Figure 2.18: Market for Media Used in Cell Culture, 2012-2019 57Figure 2.19: Market for Serum Used in Cell Culture, 2012-2019 58Figure 5.1: CIRM's Grants for Disease Types by Funding Level, 2012 110Figure 7.1: Commercially Available Regenerative Products 119Figure 7.2: Global Market for Tissue Engineering Products, 2012-2019 123Figure 7.3: Global RM Market for Cardiology and Vascular Products, 2012-2019 126Figure 7.4: Alternatives for Medtronic's Infuse 128Figure 7.5: Global Market for RM Products in Orthopedics, Musculoskeletal and Spine, 2012-2019 130Figure 7.6: Global RM Market for Neurology Products, 2012-2019 131Figure 7.7: Global RM Market for Dental Products, 2012-2019 132Figure 7.8: Global Tissue Engineering and Cell Therapy Market for Cancer Products, 2012-2019 133Figure 7.9: Global Market for RM Products in Urology, 2012-2019 134Figure 7.10: Global Market for RM Products in Skin/Integument, 2012-2019 135Figure 7.11: Global Tissue Engineering and Cell Therapy Market, 2012-2019 136Figure 7.12: U.S. Market for Tissue Engineered Skin Replacement and Substitutes, 2012-2019 137Figure 7.13: U.S. Market for RM Products in Orthopedic/Spine, 2012-2020 139Figure 7.14: U.S. Market for RM Products in Nerve Repair, 2012-2020 140Figure 7.15: U.S. Market for RM Products in Cardiovascular Therapies, 2012-2020 141Figure 7.16: U.S. Market for RM Products in Anti-Inflammatory Therapies, 2012-2020 142Figure 7.17: U.S. Market for RM Products in Diabetes, 2012-2020 143Figure 7.18: U.S. Market for Regenerative Medicines, 2012-2020 144Figure 7.19: U.S. Regenerative Medicine Market by Segment, 2020 145Figure 8.1: Global Market for Stem Cell Products, 2012-2020 148Figure 8.2: U.S. Market for Stem Cell Products, 2012-2020 151Figure 8.3: Estimated U.S. Market for Stem Cell Therapy by Type, 2020 153Figure 8.4: European Market for Stem Cell Products, 2012-2020 153Figure 8.5: Number of Autologous and Allogeneic Cell Therapy Firms in Europe 154Figure 8.6: Asia-Pacific Market for Stem Cells, 2012-2019 155Figure 8.7: Global Autologous Cell Therapy Market, 2012-2019 156Figure 9.1: Cell-Based Business Models 159Figure 9.2: Current Autologous Business Models 161Figure 9.3: Current Allogeneic Business Models 162Figure 10.1: Aastrom's Cell Expansion Process 167


Table 2.1: Commercially Available Bioengineered Skin Products 23Table 2.2: A Partial List of Companies Offering Bioreactor Systems 25Table 2.3: Number of Tissue Engineering Companies in the Five Focus Countries 28Table 2.4: Number of Tissue Engineering Firms Developing Stem Cells Seeded to Scaffolds 28Table 2.5: Number of Tissue Engineering Firms Focusing on Skin, Cartilage, Bone and Urological Products 29Table 2.6: Number of Tissue Engineering Firms Focused on Cardiovascular Products 30Table 2.7: Number of Tissue Engineering Firms Focusing on Neurological Products 30Table 2.8: Number of Tissue Engineering Firms Focusing on Pancreas, Liver and Kidney 31Table 2.9: Number of TE Firms Focused on Autologous and Allogenic Products 31Table 2.10: Major Cell Therapy Companies 36Table 2.11: Geographical Distribution of Cell Therapy Companies 38Table 2.12: Cell Therapy Products on the Market 40Table 2.13: Cell Therapy Products on the Market by Type and Application 40Table 2.14: Potential Patients for Cell Therapy in the U.S. 41Table 2.15: Number of Patients Treated with Cell Therapy Between 1988 and 2010 42Table 2.16: Cell Therapy Pipeline, 2005-2011 42Table 2.17: Number of Stem Cell Clinical Trials by Indication, 2012 43Table 2.18: Major Cell Therapy Clinical Trials for Diabetes and Estimated Enrollment Targets, 2012 44Table 2.19: Progress in Clinical Trials for Diabetes, 2012 44Table 2.20: Cell Therapy Deals, 2007-2011 49Table 2.21: Select Cell Therapy Products with FDA/EMA Regulatory Approval, 1998-2010 50Table 2.22: Cell Therapy Companies and Products 50Table 2.23: Cell Therapy Products Approved in South Korea 51Table 2.24: Selected Suppliers of Culture Media and Reagents 58Table 2.25: Selected Suppliers of In Vitro Te

To order this report: Blood_Supply,_Tissue_Banking_and_Transplantation Industry: Regenerative Medicine Markets

Contact: Nicolas BombourgReportlinkerEmail: nicolasbombourg@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
5 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,908.82 +104.02 0.58%
S&P 500 2,070.90 +0.25 0.01%
NASDAQ 4,770.5190 +5.1390 0.11%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs